Diabetes mellitus and cognitive decline;Diabetes mellitus und kognitive Störungen

Wiener Medizinische Wochenschrift

Volumn 161, Issue 21, 2011, Pages 524-530

  Iglseder, Bernhard ^a  

^a Christian Doppler Klinik   (Austria)

Author keywords

cognitive decline; dementia; Diabetes mellitus; hyperglycemia; hypoglycemia

Indexed keywords

ARTICLE; BLOOD VESSEL INJURY; COGNITIVE DEFECT; DEMENTIA; DIABETES MELLITUS; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; RISK FACTOR; MENTAL TEST;

INSULIN;

EID: 83755184174     PISSN: 00435341     EISSN: 1563258X     Source Type: Journal    
DOI: 10.1007/s10354-011-0003-x     Document Type: Article

References (52)

1. www.oedg.org/diabetesbericht. 2011.
2. Resl M, Clodi M. Diabetes and cardiovascular complications. Wien Med Wochenschr, 160: 3-7, 2010.
3. Wancata J, Musalek M, Alexandrowicz R, Krautgartner M. Number of dementia sufferers in Europe between the years 2000 and 2050. Eur Psychiatry, 18: 306-313, 2003. (Pubitemid 37461923)
4. Fratiglioni L, Launer LJ, Andersen K, Breteler MM, Copeland JR, Dartigues JF, Lobo A, Martinez-Lage J, Soininen H, Hofman A. Incidence of dementia andmajor subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology, 54: S10-S15, 2000. (Pubitemid 30390599)
5. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med, 362: 329-344, 2010.
6. Biessels GJ, Kappelle LJ. Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans, 33: 1041-1044, 2005. (Pubitemid 41659109)
7. Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes - systematic overview of prospective observational studies. Diabetologia, 48: 2460-2469, 2005. (Pubitemid 41738208)
8. van den BE, Reijmer YD, de Bresser J, Kessels RP, Kappelle LJ, Biessels GJ. A 4 year follow-up study of cognitive functioning in patients with type 2 diabetes mellitus. Diabetologia, 53: 58-65, 2010.
9. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MM. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia, 39: 1392-1397, 1996. (Pubitemid 26356072)
10. Lu FP, Lin KP, Kuo HK. Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis. PLoS One, 4: e4144, 2009.
11. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol, 5: 64-74, 2006. (Pubitemid 41790697)
12. Roberts RO, Geda YE, Knopman DS, Christianson TJ, Pankratz VS, Boeve BF, Vella A, Rocca WA, Petersen RC. Association of duration and severity of diabetes mellitus with mild cognitive impairment. Arch Neurol, 65: 1066-1073, 2008.
13. Kloppenborg RP, van den BE, Kappelle LJ, Biessels GJ. Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur J Pharmacol, 585: 97-108, 2008.
14. Middleton LE, Yaffe K. Targets for the prevention of dementia. J Alzheimers Dis, 20: 915-924, 2010.
15. Allen KV, Frier BM, Strachan MW. The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol, 490: 169-175, 2004. (Pubitemid 38482170)
16. Xu W, Qiu C, Winblad B, Fratiglioni L. The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes, 56: 211-216, 2007.
17. Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L. Diabetesmellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology, 63: 1181-1186, 2004. (Pubitemid 39350014)
18. Sanz C, Andrieu S, Sinclair A, Hanaire H, Vellas B. Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease. Neurology, 73: 1359-1366, 2009.
19. Middleton LE, Yaffe K. Promising strategies for the prevention of dementia. Arch Neurol, 66: 1210-1215, 2009.
20. Middleton LE, Barnes DE, Lui LY, Yaffe K. Physical activity over the life course and its association with cognitive performance and impairment in old age. J Am Geriatr Soc, 58: 1322-1326, 2010.
21. Craft S. Insulin resistance syndrome and Alzheimer's disease: ageand obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging, 26(Suppl 1): 65-69, 2005.
22. de la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis, 7: 45-61, 2005. (Pubitemid 40387184)
23. Zhu X, Perry G, Smith MA. Insulin signaling, diabetes mellitus and risk of Alzheimer disease. J Alzheimers Dis, 7: 81-84, 2005. (Pubitemid 40387186)
24. Umegaki H. Pathophysiology of cognitive dysfunction in older people with type 2 diabetes: vascular changes or neurodegeneration? Age Ageing, 39: 8-10, 2010.
25. Fishel MA, Watson GS, Montine TJ, Wang Q, Green PS, Kulstad JJ, Cook DG, Peskind ER, Baker LD, Goldgaber D, Nie W, Asthana S, Plymate SR, Schwartz MW, Craft S. Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol, 62: 1539-1544, 2005. (Pubitemid 41434558)
26. Qiu WQ, Folstein MF. Insulin, insulin-degrading enzyme and amyloid- beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging, 27: 190-198, 2006. (Pubitemid 43038542)
27. Matsuzaki T, Sasaki K, Tanizaki Y, Hata J, Fujimi K,Matsui Y, Sekita A, Suzuki SO, Kanba S, Kiyohara Y, Iwaki T. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology 75: 764-770, 2010.
28. Rasgon NL, Kenna HA, Wroolie TE, Kelley R, Silverman D, Brooks J, Williams KE, Powers BN, Hallmayer J, Reiss A. Insulin resistance and hippocampal volume in women at risk for Alzheimer's disease. Neurobiol Aging, in press; doi: 10.1016/j.neurobiolaging.2009.12.005
29. Jolivalt CG, Lee CA, Beiswenger KK, Smith JL, OrlovM, Torrance MA, Masliah E. Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J Neurosci Res, 86: 3265-3274, 2008.
30. Kalaria RN, Harik SI. Abnormalities of the glucose transporter at the blood-brain barrier and in brain in Alzheimer's disease. Prog Clin Biol Res, 317: 415-421, 1989.
31. de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetesevidence reviewed. J Diabetes Sci Technol, 2: 1101-1113, 2008.
32. Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs, 17: 27-45, 2003. (Pubitemid 36044347)
33. Heo JH, Lee ST, Kon C, Park HJ, Shim JY, Kim M. White matter hyperintensities and cognitive dysfunction in Alzheimer disease. J Geriatr Psychiatry Neurol, 22: 207-212, 2009.
34. Ahtiluoto S, Polvikoski T, Peltonen M, Solomon A, Tuomilehto J, Winblad B, Sulkava R, Kivipelto M: Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology, 75: 1195-1202, 2010.
35. Musen G, Lyoo IK, Sparks CR, Weinger K, Hwang J, Ryan CM, Jimerson DC, Hennen J, Renshaw PF, Jacobson AM. Effects of type 1 diabetes on gray matter density as measured by voxel-based morphometry. Diabetes, 55: 326-333, 2006. (Pubitemid 43343260)
36. Lobnig BM, Kromeke O, Optenhostert-Porst C, Wolf OT. Hippocampal volume and cognitive performance in long-standing Type 1 diabetic patients without macrovascular complications. Diabet Med, 23: 32-39, 2006.
37. Hershey T, Perantie DC, Wu J, Weaver PM, Black KJ, White NH. Hippocampal volumes in youth with type 1 diabetes. Diabetes, 59: 236-241, 2010.
38. Seaquist ER. The final frontier: how does diabetes affect the brain? Diabetes, 59: 4-5, 2010.
39. Zhu X, Perry G, Smith MA. Insulin signaling, diabetes mellitus and risk of Alzheimer disease. J Alzheimers Dis, 7: 81-84, 2005. (Pubitemid 40387186)
40. Valente T, Gella A, Fernandez-Busquets X, Unzeta M, Durany N. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Neurobiol Dis, 37: 67-76, 2010.
41. Guglielmotto M, Aragno M, Tamagno E, Vercellinatto I, Visentin S, Medana C, Catalano MG, Smith MA, Perry G, Danni O, Boccuzzi G, TabatonM. AGEs/RAGE complex upregulates BACE1 via NF-kappaB pathway activation. Neurobiol Aging, in press; doi: 10.1016/j. neurobiolaging.2010.05.026
42. McCall AL. Cerebral glucose metabolism in diabetes mellitus. Eur J Pharmacol, 490: 147-158, 2004. (Pubitemid 38482168)
43. Northam EA, Rankins D, Lin A, Wellard RM, Pell GS, Finch SJ, Werther GA, Cameron FJ. Central nervous system function in youth with type 1 diabetes 12 years after disease onset. Diabetes Care, 32: 445-450, 2009.
44. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA, 301: 1565-1572, 2009.
45. Kempermann G, Van Praag H, Gage FH. Activity-dependent regulation of neuronal plasticity and self repair. Prog Brain Res, 127: 35-48, 2000. (Pubitemid 35461255)
46. Van Praag H, Kempermann G, Gage FH. Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus. Nat Neurosci, 2: 266-270, 1999. (Pubitemid 30491298)
47. Abbas T, Faivre E, Holscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. Behav Brain Res, 205: 265-271, 2009.
48. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry, 13: 950-958, 2005. (Pubitemid 46638661)
49. Landreth G, Jiang Q, Mandrekar S, Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics, 5: 481-489, 2008. (Pubitemid 351952487)
50. Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey WH, Craft S. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis, 13: 323-331, 2008. (Pubitemid 352039034)
51. Hsu CC, Wahlqvist ML, Lee MS, Tsai HN. Incidence of Dementia is Increased in Type 2 Diabetes and Reduced by the Use of Sulfonylureas and Metformin. J Alzheimers Dis, 24: 485-493, 2011.
52. Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, Ma T, Thompson RC, Zhao Y, Smith L, Gasparini L, Luo Z, Xu H, Liao FF. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci USA, 106: 3907-3912, 2009.